**RESULTS**

- MIC distributions of cefepime-tazobactam combinations are shown in Figure 1, with summary data for comparators in Table 1. Findings were:
  - ESBL producers: good synergy was seen, but most isolates were susceptible to cefepime-tazobactam 1+4 mg/L, all were susceptible at 8+8 mg/L.
  - AmpC producers: cefepime-tazobactam reduced cefepime MICs of AmpC producers (35) 24/35 isolates were susceptible to cefepime-tazobactam 1+4 mg/L, all were susceptible at 8+8 mg/L.
  - K. oxytoca hyperproducing K1 enzyme: all isolates were susceptible at 1+4 mg/L, all were susceptible at 8+8 mg/L.
  - MBL producers: cefepime-tazobactam reduced cefepime MICs of MBL producers (35) 24/35 isolates were susceptible to cefepime-tazobactam 1+4 mg/L, all were susceptible at 8+8 mg/L.
  - OXA-48-like enzyme producers: cefepime-tazobactam reduced cefepime MICs of OXA-48-like producers (15) 24/35 isolates were susceptible to cefepime-tazobactam 1+4 mg/L, all were susceptible at 8+8 mg/L.

**BACKGROUND**

- Cefepime is a promising partner for many infection types, but:
  - β-lactamase inhibitor combinations (e.g. ceftolozane, as evidenced by the need for a lower tazobactam threshold concentration and a weaker labile to KPC enzymes [10].
  - Cefepime is an attractive alternative partner, being relatively stable to AmpC and less labile than piperacillin-tazobactam and meropenem.

**METHODS & MATERIALS**

- Organisms (n=270, see Results) were recent isolates from Public Health England, London, UK; University of East Anglia, Norwich, UK.
- Geometric mean MICs of cefepime and its tazobactam combinations are available in India [7] but have not been formally evaluated and deliver only low dosages of tazobactam (250-750 mg/day).
- Most K. pneumoniae (35) were inhibited by cefepime-tazobactam 8+8 mg/L, but K. oxytoca (5) were not.

**CONCLUSIONS**

- Cefepime-tazobactam (WCK 4282) achieved good activity, even against a 1+4 mg/L reference point, against Enterobacteriaceae with ESBLs, AmpC or K1 enzymes.
- Cefepime resistance in A. baumannii was also weakly dependent on cefepime-tazobactam concentration tested.

**REFERENCES**